drugset / Trial / NCT03741530

Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage

NCT03741530

Completed 220 enrolled Xijing Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of the present study is to explore the efficacy of small doses of oral glibenclamide on brain edema after acute primary intracerebral hemorrhage (ICH), and improving the prognosis of patients.

Timeline

Start
2018-12-15
Primary completion
2020-09-23
Completion
2020-09-23

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Glyburide Small molecule 1.25 mg Oral